Although cost-effectiveness analyses
are needed to more fully evaluate a screening strategy in Iran,
screenings at ages 35, 40, and 45, with an additional visit at age 55 or
60 may provide an optimal screening strategy in Iran and other Muslim
countries where the incidence rate is low and cervical cancer typically
occurs in women 40–65 years old